ArticleJournal of neurology2025
Stroke thrombolysis for patients with intracranial aneurysms: a nationwide cohort study.
Article in Journal of neurology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Article
- Intravenous Thrombolysis for Ischemic Stroke Patients with Pituitary Neoplasms: A Nationwide Study and Scoping Review.NeuroSci · 2026Article
- Tissue Plasminogen Activator as an Approved Strategy for Ischemic Stroke: A Review of tPA's Structure, Mechanism of Action and the Novel Targeting Methods.Journal of molecular neuroscience : MN · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe safety of intravenous thrombolysis (IVT) in acute ischemic stroke (AIS) patients with underlying unruptured intracranial aneurysms (UIAs) is unclear. This study evaluates IVT safety and efficacy in AIS patients with UIAs in routine clinical practice.
methodsUsing the 2016-2022 Nationwide Readmissions Database, we conducted a retrospective cohort study of AIS patients with National Institutes of Health Stroke Scale (NIHSS) scores ≥ 6. Patients with a diagnosis of UIA were identified. Patients with intracranial tumors and other cerebrovascular malformations were excluded. Multivariable logistic regression assessed the association between IVT and outcomes, including routine discharge, mortality, subarachnoid hemorrhage (SAH), and intraparenchymal hemorrhage (IPH). Interaction analyses compared treatment effects between UIA and non-UIA patients.
resultsOf 689,285 AIS patients, 11,687 (1.7%) had UIAs; 25.0% received IVT. Among UIA patients, IVT was associated with higher rates of routine discharge [adjusted OR (aOR) 2.25 (95%CI 1.95-2.59)] and lower mortality [aOR 0.64 (95%CI 0.48-0.87)]. IVT did not increase SAH risk in UIA patients [aOR 0.97 (95%CI 0.63-1.49)]. IVT was linked to higher IPH risk for UIA patients [aOR 1.34 (95%CI 1.06-1.70)], though this association was also found among non-UIA patients with a similar magnitude (p-interaction = 0.91). Compared to IVT-treated non-UIA patients, IVT-treated UIA patients were significantly more likely to experience routine discharge [OR 1.20 (95%CI 1.02-1.40)], despite having significantly higher odds of SAH [OR 1.97 (95%CI 1.19-3.26)].
conclusionsAmong AIS patients with UIAs, IVT was associated with better functional outcomes without excess risk of SAH. UIAs do not significantly alter the risk profile of IVT treatment.
Indexed as
Identifiers
40717205What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.